The publication’s “Pre$cription for Power” database includes 12,000 donations from 14 large, publicly traded drugmakers to patient groups in 2015, which is the most recent year with available Internal Revenue Service documents. KHN used information from drug companies’ charitable giving reports and federal 990 regulatory filings to compile the database.
Here are four database findings.
1. The 14 drugmakers spent much less on lobbying — about $63 million — than patient group donations in 2015.
2. Six drug companies donated a million dollars or more to advocacy groups representing patients who use their drugs.
3. Of 1,200 patient groups identified in the database, 594 accepted money from the pharmaceutical industry.
4. Drug industry donations accounted for at least 20 percent of total revenue for 15 patient groups, some with annual revenues as high as $3.6 million.
More articles on supply chain:
Procter & Gamble eyes Pfizer’s consumer health business: 4 things to know
Taking the Operating Room Supply Chain Processes from ‘Necessary Evil’ to ‘Essential Ally’
Ohio bans ‘gag orders’ in PBM contracts: 3 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
